70026-89-0Relevant academic research and scientific papers
TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS
-
Page/Page column 62, (2021/02/12)
Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X11 and X22 are independently C or N, provided that zero or one of X11 and X22 is N; Ring A represented by the structure is: or; and Q, R11, R22, R33, R44, R66, and p are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.
BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS
-
Page/Page column 553; 554, (2018/03/25)
Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.
THROMBIN INHIBITORS
-
Page column 17, (2010/01/30)
Compounds of the invention, useful as thrombin inhibitors and having therapeutic value in for example, preventing coronary artery disease, have the following structure: or a pharmaceutically acceptable salt thereof, whereinA is whereinY 1 and Y 2 are independentlyhydrogen,C 1-4 alkyl,C 1-4 alkoxy,F uH v C(CH 2) 0-1 O--, wherein u and v are either 1 or 2, provided that when u is 1, v is 2, and when u is 2, v is 1,C 3-7 cycloalkyl,thio C 1-4 alkyl,C 1-4 sulfinylalkyl,C 1-4 sulfonylalkyl, halogencyano, ortrifluoromethyl, andwherein b is 0 or 1.
Bicyclic pyridones as potent, efficacious and orally bioavailable thrombin inhibitors
Coburn, Craig A.,Rush, Diane M.,Williams, Peter D.,Homnick, Carl,Lyle, Elizabeth A.,Lewis, S. Dale,Lucas Jr., Bobby J.,Di Muzio-Mower, Jillian M.,Juliano, Marylou,Krueger, Julie A.,Vastag, Kari,Chen, I-Wu,Vacca, Joseph P.
, p. 1069 - 1072 (2007/10/03)
A new class of conformationally constrained thrombin inhibitors is described. These compounds contain a unique bicyclic pyridone scaffold which serves as a P3P2 dipeptide surrogate. The synthesis and antithrombotic activity of these inhibitors is reported. (C) 2000 Elsevier Science Ltd. All rights reserved.
